Published in J Am Acad Dermatol on April 14, 2008
Osteoporosis: now and the future. Lancet (2011) 5.81
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas (2010) 1.51
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs (2009) 1.26
Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep (2012) 0.98
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir Res (2011) 0.89
Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology (Oxford) (2013) 0.84
Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging (2012) 0.79
[Cathepsin K antagonists: preclinical and clinical data]. Wien Med Wochenschr (2015) 0.77
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporos Int (2016) 0.77
Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med (2013) 0.76
Current and emerging therapies for the treatment of osteoporosis. J Exp Pharmacol (2010) 0.75
Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol (2017) 0.75
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocr Rev (2017) 0.75
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol (2007) 2.17
Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol (2014) 2.13
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs (2014) 1.99
VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam. Mol Biol Cell (2002) 1.97
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 1.82
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol (2006) 1.77
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol (2003) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges (2010) 1.60
Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol (2005) 1.54
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol (2003) 1.43
Allergy and the bone: unexpected relationships. Ann Allergy Asthma Immunol (2011) 1.41
Annular lichenoid dermatitis of youth. J Am Acad Dermatol (2003) 1.40
Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol (2006) 1.40
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res (2004) 1.32
Subcutaneous sarcoidosis: report of two cases and review of the literature. Clin Rheumatol (2011) 1.29
Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res (2012) 1.26
Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol (2007) 1.26
Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24
ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol (2005) 1.23
The role of chemokines in allergic contact dermatitis. Arch Dermatol Res (2002) 1.22
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr (2008) 1.21
Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost (2009) 1.21
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Long-term effects of amino-bisphosphonates on circulating γδ T cells. Calcif Tissue Int (2012) 1.18
Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther (2010) 1.16
Drug-induced lupus erythematosus. Arch Dermatol Res (2008) 1.16
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 1.15
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol (2009) 1.09
STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J (2010) 1.09
Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol (2010) 1.09
Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol (2003) 1.09
Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int (2013) 1.08
Rapid skeletal turnover in radiographic mimic of osteopetrosis might be secondary to systemic mastocytosis [corrected]. J Bone Miner Res (2015) 1.08
Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood (2002) 1.08
Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy (2005) 1.08
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc (2002) 1.07
Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology (2008) 1.06
The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab (2011) 1.05
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol (2005) 1.03
Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int (2013) 1.03
The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) (2012) 1.02
Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology (Oxford) (2012) 1.00
Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol (2002) 1.00
Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release. J Cell Physiol (2004) 0.99
Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol (2010) 0.99
Chemokine networks in inflammatory skin diseases. Eur J Dermatol (2004) 0.98
Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol (2009) 0.98
25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone (2009) 0.97
Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg (2012) 0.97
Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. Nat Clin Pract Rheumatol (2008) 0.97
The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol (2006) 0.97
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol (2008) 0.96
H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol (2004) 0.96
Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol (2010) 0.96
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol (2002) 0.95
Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc (2012) 0.95
Mid-dermal elastolysis: a clinical, histologic, and immunohistochemical study of 11 patients. J Am Acad Dermatol (2003) 0.95
Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol (2002) 0.95
Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃. J Clin Endocrinol Metab (2012) 0.94
Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol (2016) 0.93
Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol (2010) 0.93
Epithelial cell shape and Rho small GTPases. Novartis Found Symp (2005) 0.93
Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int (2013) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Endometriosis of umbilical cicatrix: case report and review of the literature. Acta Dermatovenerol Croat (2008) 0.92
Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. J Invest Dermatol (2006) 0.92
Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf) (2003) 0.92
Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol (2004) 0.91
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. Hum Hered (2006) 0.91
Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets (2008) 0.91
Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J Immunol (2002) 0.91
Activin A induces Langerhans cell differentiation in vitro and in human skin explants. PLoS One (2008) 0.91
Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat (2010) 0.91
Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women. Bone (2009) 0.91
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab (2009) 0.91
The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. J Clin Densitom (2003) 0.90
Bone turnover markers in patients with osteogenesis imperfecta. Bone (2004) 0.90
Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges (2012) 0.89
Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity (2010) 0.89